FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

VESSEY RUPERT		 2. Issuer Name and Ticker or Trading Symbol

CELGENE CORP /DE/ [ CELG ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
PRES., RESEARCH AND EARLY DEV.
(Last)          (First)          (Middle)

C/O CELGENE CORPORATION, 86 MORRIS AVENUE		 3. Date of Earliest Transaction (MM/DD/YYYY)

11/20/2019
(Street)

SUMMIT, NJ 07901
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/20/2019  A  8634 A$0 (1)22812 D 
 
Common Stock 11/20/2019  A  13906 A$0 (1)36718 D 
 
Common Stock 11/20/2019  A  24209 A$0 (1)60927 D 
 
Common Stock 11/20/2019  D  60927 D$0 (2)0 D 
 
Common Stock 11/20/2019  D  613 D$0 (2)0 I 401(k) Plan 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $118.57 11/20/2019  D     19142   (3)(4)2/2/2025 Common Stock 19142 $0 (4)0 D 
 
Stock Option (right to buy) $109.90 11/20/2019  D     3125   (3)(4)5/4/2025 Common Stock 3125 $0 (4)0 D 
 
Stock Option (right to buy) $132.56 11/20/2019  D     3125   (3)(4)7/27/2025 Common Stock 3125 $0 (4)0 D 
 
Stock Option (right to buy) $114.08 11/20/2019  D     3125   (3)(4)11/9/2025 Common Stock 3125 $0 (4)0 D 
 
Stock Option (right to buy) $100.80 11/20/2019  D     2344   (3)(4)2/1/2026 Common Stock 2344 $0 (4)0 D 
 
Stock Option (right to buy) $104.97 11/20/2019  D     9680   (3)(4)5/2/2026 Common Stock 9680 $0 (4)0 D 
 
Stock Option (right to buy) $114.69 11/20/2019  D     12906   (3)(4)8/1/2026 Common Stock 12906 $0 (4)0 D 
 
Stock Option (right to buy) $102.18 11/20/2019  D     31210   (3)(4)10/31/2026 Common Stock 31210 $0 (4)0 D 
 
Stock Option (right to buy) $113.18 11/20/2019  D     12906   (3)(4)1/30/2027 Common Stock 12906 $0 (4)0 D 
 
Stock Option (right to buy) $124.06 11/20/2019  D     11384   (3)(4)5/1/2027 Common Stock 11384 $0 (4)0 D 
 
Stock Option (right to buy) $135.41 11/20/2019  D     11384   (3)(4)7/31/2027 Common Stock 11384 $0 (4)0 D 
 
Stock Option (right to buy) $100.97 11/20/2019  D     26308   (3)(4)10/30/2027 Common Stock 26308 $0 (4)0 D 
 
Stock Option (right to buy) $103.26 11/20/2019  D     11384   (3)(4)1/29/2028 Common Stock 11384 $0 (4)0 D 
 
Stock Option (right to buy) $83.13 11/20/2019  D     18257   (3)(4)5/8/2028 Common Stock 18257 $0 (4)0 D 
 
Stock Option (right to buy) $88.91 11/20/2019  D     18257   (3)(4)7/30/2028 Common Stock 18257 $0 (4)0 D 
 
Stock Option (right to buy) $71.43 11/20/2019  D     18257   (3)(4)10/29/2028 Common Stock 18257 $0 (4)0 D 
 
Restricted Stock Unit $0 (5)11/20/2019  D     5756   (6) (6)Common Stock 5756 $0 (6)0 D 
 
Restricted Stock Unit $0 (5)11/20/2019  D     3120   (6) (6)Common Stock 3120 $0 (6)0 D 
 
Restricted Stock Unit $0 (5)11/20/2019  D     9271   (6) (6)Common Stock 9271 $0 (6)0 D 
 
Restricted Stock Unit $0 (5)11/20/2019  D     5794   (6) (6)Common Stock 5794 $0 (6)0 D 
 
Restricted Stock Unit $0 (5)11/20/2019  D     37660   (6) (6)Common Stock 37660 $0 (6)0 D 
 
Explanation of Responses:
(1) Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
(2) Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
(3) This option was fully exercisable.
(4) Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
(5) Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
(6) Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
VESSEY RUPERT
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT, NJ 07901

PRES., RESEARCH AND EARLY DEV.
Signatures
/s/ Jonathan Biller, Attorney-in-Fact11/22/2019
**Signature of Reporting PersonDate
Celgene (NASDAQ:CELGZ)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Celgene.
Celgene (NASDAQ:CELGZ)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Celgene.